Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Six-Month Depot Leuprolide in Prostate Cancer
NCT00056654Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Mar 2003
- Primary completion
- Jul 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by Abbott Laboratories. Primary endpoint: Suppression of serum testosterone (<=50 ng/dL) and maintenance of suppression at Week 52. Started Mar 2003; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00056654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056654.